SCHEMBL23583166

SCHEMBL23583166

CCNc1ccc2c(n1)CCO2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.35
CACNA1C Q13936 2/20 0.34
SCN5A Q14524 2/20 0.34
KCNH2 Q12809 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PKM P14618 3/20 0.33
PTGDR Q13258 1/20 0.32
HCAR3 P49019 1/20 0.32
EED O75530 1/20 0.31
SUZ12 Q15022 1/20 0.31
EZH2 Q15910 1/20 0.31
DYRK1A Q13627 1/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
KMT2A Q03164 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
TAS1R3 Q7RTX0 1/20 0.30
TAS1R1 Q7RTX1 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21245930 0.81 TYK2 (0.42) TYK2KDM4EPKMDYRK1AKMT2A
SCHEMBL8103788 0.77 DYRK1A (0.36) TYK2PKMDYRK1AKMT2A
SCHEMBL21227320 0.77 TYK2 (0.35) TYK2PKMHCAR3DYRK1A
SCHEMBL13668627 0.74 DYRK1A (0.36) KDM4EEEDSUZ12EZH2DYRK1A
SCHEMBL15435737 0.71 DYRK1A (0.39) KDM4EPKMDYRK1A
SCHEMBL3486435 0.69 LMNA (0.54) KDM4EPKMKMT2A
SCHEMBL21935993 0.67 DYRK1A (0.35) PKMDYRK1A
SCHEMBL21333142 0.67 DYRK1A (0.35) KDM4EPKMDYRK1A
SCHEMBL29618341 0.67 DYRK1A (0.46) KDM4EPKMDYRK1A
SCHEMBL30848471 0.67 DYRK1A (0.35) KDM4EPKMDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885CACNA1C 4649/4885SCN5A 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.